New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Pa...(n and oxygencontent measurements along w...),Health

Date:3/6/2008

n and oxygen content measurements, along with carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet), pleth variability index (PVI(TM)), perfusion index (PI), oxygen saturation (SpO2) and pulse rate -- all on one screen, with one device and one sensor, was equally impressive."

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and pleth variability index (PVI(TM)), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com. '/>"/>

SOURCE Masimo Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
2. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
3. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
4. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
5. EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
6. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
7. Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)
8. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
9. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
10. Treatment of First Patient in Phase I Clinical Trial of Bionomics Anti-Cancer Drug BNC105
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial